Scipher Medicine vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Scipher Medicine uses AI and network medicine to match autoimmune patients to effective therapies; PrismRA is the first molecular test approved to predict TNF inhibitor response in RA; $110M raised.
About
Scipher Medicine is a precision immunology company headquartered in Waltham, Massachusetts, applying AI and network biology to solve one of medicine's most persistent problems: predicting which therapy a patient with an autoimmune disease will actually respond to. The company's core platform integrates protein-protein interaction mapping, RNA sequencing data from the largest non-oncology clinico-transcriptomic biobank, and machine learning to identify molecular signatures that distinguish patients likely to respond from those likely to fail a given therapy.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.